Kynam Capital Management, LP Centessa Pharmaceuticals PLC Transaction History

Kynam Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$5.52 - $8.03 $1.59 Million - $2.31 Million	-287,768 Reduced 39.39%	442,704 $3.52 Million
Q3 2023 Nov 14, 2023	BUY	$6.01 - $8.24 $8,383 - $11,494	1,395 Added 0.19%	730,472 $4.73 Million
Q1 2023 May 15, 2023	SELL	$3.03 - $4.0 $14,692 - $19,396	-4,849 Reduced 0.66%	729,077 $2.81 Million
Q4 2022 Feb 14, 2023	BUY	$3.05 - $4.19 $7,335 - $10,076	2,405 Added 0.33%	733,926 $2.28 Million
Q3 2022 Nov 14, 2022	SELL	$3.8 - $5.91 $100,042 - $155,592	-26,327 Reduced 3.47%	731,521 $2.94 Million
Q2 2022 Aug 15, 2022	BUY	$3.18 - $9.85 $282,218 - $874,167	88,748 Added 13.26%	757,848 $3.69 Million
Q1 2022 May 13, 2022	BUY	$7.45 - $11.59 $3.2 Million - $4.98 Million	430,059 Added 179.91%	669,100 $6 Million
Q4 2021 Feb 14, 2022	BUY	$10.99 - $17.54 $2.63 Million - $4.19 Million	239,041 New	239,041 $2.69 Million

108

118M

5.9K

53K

Ticker CNTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,339,296
Market Cap $1.59B
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Kynam Capital Management, LP with notifications on news.